CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …

Leukemia cells prevent immune system from clearing tumor cells by inducing the
immunosuppression of the bone marrow (BM) microenvironment. In recent years, further …

Blinatumomab is a BiTE®(bispecific T‐cell engager) molecule that redirects CD3+ T‐cells to
engage and lyse CD19+ target cells. Here we demonstrate that subcutaneous (SC) …

Preclinical studies suggest that Bcl-2 inhibition with venetoclax has antileukemic activity in
acute lymphoblastic leukemia (ALL) and may synergize with conventional chemotherapy …

Simple Summary Immunotherapy has improved the outcome of relapsed/refractory B-
lymphoblastic leukemia. However, little is known about the outcome after recurrence and re …

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) constitutes a
distinctive cytogenetic entity associated with challenging outcomes, particularly in adult …

Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first
evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute …

Acute lymphoblastic leukemia (ALL) is one of the most rapidly changing hematological
malignancies with advanced understanding of the genetic landscape, detection methods of …

There have been major paradigm shifts in the treatment of Philadelphia chromosome
negative (Ph-) acute lymphoblastic leukemia (ALL) in the last decade with the introduction of …

The early mortality rate after a medical procedure or treatment has been a historical
measure of quality of care delivery. It was originally developed to assess the risk of surgeries …